Earnings Releases, Conference Call Schedule, Acquisitions, Drug Launches, and Initiation of Study - Research Reports on KeyCorp, Itau Unibanco, BD, Mylan and GlaxoSmithKline

NEW YORK, October 20, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding KeyCorp. (NYSE: KEY), Itau Unibanco Holding S.A. (NYSE: ITUB), Becton, Dickinson and Company (NYSE: BDX), Mylan Inc. (NASDAQ: MYL) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7300-100free.

--
KeyCorp. Research Reports
On October 15, 2014, KeyCorp. (KeyCorp) announced its Q3 2014 financial results. Net income from continuing operations attributable to KeyCorp common shareholders reported at $197 million, or $0.23 per common share, low compared to $229 million, or $0.25 per common share, in Q3 2013. "Key's third quarter reflects solid results in our core businesses as we continue to execute on our relationship strategy, while remaining disciplined in managing risk and our strong capital position," said Chairman and CEO Beth Mooney. "Compared with the same period last year, average loans increased 5%, driven by growth in commercial, financial and agricultural loans. We saw positive trends in several of our fee-based businesses, while we realized lower gains from principal investing and leveraged lease terminations. In the third quarter, the number of retail clients grew and we improved sales productivity across both the Community Bank and Corporate Bank." On the same day, shares of KeyCorp declined 5.8% to close at $12.14. Wall Street Journal reported that the fall followed decline in the Q3 2014 profits. The full research reports on KeyCorp are available to download free of charge at:

http://www.analystsreview.com/Oct-20-2014/KEY/report.pdf

--
Itau Unibanco Holding S.A. Research Reports
As per the Investor section of Itau Unibanco Holding S.A's (Itau Unibanco) official website, the Company has scheduled its Q3 2014 financial results conference call on November 5, 2014, at 9:30 a.m. New York time. According to Bloomberg Businessweek's analysts, the Company is expected to report Q3 2014 EPS of $0.40 on revenues of $23.0 billion. The full research reports on Itau Unibanco are available to download free of charge at:

http://www.analystsreview.com/Oct-20-2014/ITUB/report.pdf

--
Becton, Dickinson and Company Research Reports
On October 13, 2014, Becton, Dickinson and Company (BD) announced that it has acquired GenCell Biosystems, a privately-held Irish biotech company that has developed proprietary technologies to address key biological analysis protocols. "We are excited with the GenCell Biosystems acquisition as it provides BD entry into the Next Generation Sequencing market, a fast-growing segment with the potential to have a significant impact on healthcare," said Linda Tharby, Group President, BD. "The acquisition gives BD access to the NGS market with a differentiated platform that will provide a base to further grow our genomics offerings." Kieran Curran, CEO and Founder of GenCell, added, "We are looking forward to joining with BD to provide great solutions for our current and future customers in Next Generation Sequencing. In a short amount of time we have been able to move CLC technology from concept to product. We believe we will now be able to scale up and introduce further transformative innovation in NGS-related segments." The full research reports on BD are available to download free of charge at:

http://www.analystsreview.com/Oct-20-2014/BDX/report.pdf

--
Mylan Inc. Research Reports
On October 3, 2014, Mylan Inc. (Mylan) announced the U.S. launch of its Lamivudine and Zidovudine Tablets USP, 150 mg/300 mg, which is the generic version of Viiv's Combivir. Mylan informed that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of HIV-1 infection in combination with other antiretroviral (ARV) agents. The Company stated that it has begun shipping this product, which would further strengthen its growing ARV portfolio in the U.S. market. Mylan added that as per IMS Health, Lamivudine and Zidovudine Tablets USP, 150 mg/300 mg, had U.S. sales of approximately $118.5 million for the 12 months ended June 30, 2014. The full research reports on Mylan are available to download free of charge at:

http://www.analystsreview.com/Oct-20-2014/MYL/report.pdf

--
GlaxoSmithKline plc Research Reports
On October 7, 2014, GlaxoSmithKline plc's (GlaxoSmithKline) Company, Stiefel announced the initiation of a phase III study to evaluate the efficacy and safety of subcutaneous ofatumumab in patients with pemphigus vulgaris, a rare autoimmune skin disorder. The Company informed that the global study will assess disease remission in patients with pemphigus vulgaris who are treated with subcutaneous ofatumumab as add-on treatment to oral steroids, which is the global standard-of-care. As per Stiefel, in this global, multicentre, randomised, double-blind, placebo-controlled, parallel-group study (OPV116910), subcutaneous ofatumumab will be administered at a dose of 20 mg every four weeks (following two initial loading doses) for a total of 56 weeks. Dr. Kathy Rouan, Senior Vice President and Head of R&D, Stiefel said, "The initiation of this study is an important step towards providing a potential new treatment option for patients suffering from this painful and potentially debilitating skin disease." The full research reports on GlaxoSmithKline are available to download free of charge at:

http://www.analystsreview.com/Oct-20-2014/GSK/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review